Following its buyout by private equity firm, Madison Dearborn Partners, Alcami has refocused on ‘high growth’ market segments, which has also seen it launch Alcami Biologics.
The latest step in its reorganization sees the company divest its preclinical and early-stage active pharmaceutical ingredient (API) facility in Weert, Netherlands.
MercachemSyncom, a mid-size contract research organization (CRO), formed in 2017 by a merger, will add the facility to its portfolio for an undisclosed sum.
According to Alcami’s CCO, Chad Telgenhof, the divestiture will allow the company to invest in other areas of its network, particularly in ‘high growth market segments’.
However, the contract development and manufacturing organization (CDMO) will hold onto its European sales and business development team to continue to work with its Europe-based clients.
The move means that Alcami will retain one API manufacturing facility, located in Wisconsin, US.
Though the company has scaled back in Europe, in December of last year it announced investment of $17m (€15.2m) into its North Charleston, South Carolina facility.
The funds will be used to add 6,000-square-feet of space, increasing the capacity of the facility’s sterile drug development and manufacturing operations. The expansion is expected to be completed in 2021.